header logo image


Page 1,508«..1020..1,5071,5081,5091,510..1,5201,530..»

Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

February 23rd, 2012 6:50 pm

Japanese researchers have been able to improve the symptoms of Parkinson's disease in monkeys by transplanting nerve cells derived from embryonic stem cells into their brains, the team has announced.

The finding is the world's first reported success of its kind with a primate, according to the research team led by associate professor Jun Takahashi of Kyoto University's Institute for Frontier Medical Sciences. It has been released in the online edition of US journal Stem Cells.

After the transplant, the monkeys, which had been almost unable to move, showed improvements in their symptoms to the point where they became able to walk on their own, the team said.

Parkinson's disease is a neurological illness believed to be caused by a deficit of the neurotransmitter dopamine in the brain.

Embryonic stem cells, which have the potential to become almost any type of tissue, are harvested from inside a blastocyst, which develops from a mammalian egg cell about a week after it is fertilised.

Takahashi's research team used the embryonic stem cells to cultivate a cell mass in which 35 per cent of the cells were dopamine-producing neurons.

These neurons then were transplanted into the four crab-eating monkeys, whose conditions were observed over a one-year period.

According to the study, the monkeys exhibited reduced shaking of their limbs half a year later. They had remained nearly motionless inside their cages all day long before the transplant, but the improvement of their symptoms eventually enabled them to occasionally walk around the cages.

The research team confirmed that normal nerve cells had been created in their brains.

The finding could mark a major breakthrough for applying embryonic stem cells in clinical settings, experts said. The Health, Labour and Welfare Ministry has been encouraging researchers to study the clinical applications of not only stem cells, but also induced pluripotent stem cells, which also can grow into many kinds of human cells.

Takahashi's team has already performed experiments to transplant iPS cells into monkeys' brains.

"We'll make further efforts to enhance the safety of these cell transplants," Takahashi said. "And we hope to start clinical application studies as early as three years from now."

Go here to read the rest:
Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

Read More...

Bone Marrow Prolotherapy at Caring Medical – Dr. Ross Hauser – Video

February 23rd, 2012 6:49 pm

28-12-2010 13:43 Ross Hauser, MD is a full time Prolotherapy physician in Chicago land. He offers comprehensive Prolotherapy, including Bone Marrow Prolotherapy, also known as Stem Cell Prolotherapy. In this video, he discusses the stem cell treatment and how the bone marrow is obtained and administered. If you are interested in Prolotherapy, please visit: http://www.caringmedical.com

Originally posted here:
Bone Marrow Prolotherapy at Caring Medical - Dr. Ross Hauser - Video

Read More...

Global Tissue Engineering Market Review Recently Published at MarketPublishers.com

February 23rd, 2012 6:46 pm

New market research report “Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview” developed by Industry Experts has been recently published by Market Publishers Ltd. The report reveals that the global market for tissue engineering is projected to touch USD 27 billion by 2018 from an estimated USD 6.6 billion in 2008, witnessing a healthy CAGR of 15%.

London, UK (PRWEB) February 22, 2012

The global market for tissue engineering is projected to touch USD 27 billion by 2018 from an estimated USD 6.6 billion in 2008, witnessing a healthy CAGR of 15%. Factors that are expected to influence this market and its explosive growth include political forces, government funding, clinical trial results, fluctuating industry investment and an increasing awareness among both physicians and the general public of the accessibility of cell therapies for medical applications.

New market research report “Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview” developed by Industry Experts has been recently published by Market Publishers Ltd.

Report Details:

Title: Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview

Published: February, 2012

Pages: 153

Price: US$ 3,600

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/tissue_engineering_combination_of_cells_engineering_a_global_market_overview.html

The report provides a thorough examination of the market for tissue engineering globally and across individual regions including the United States, Europe, Asia-Pacific and ROW. The study features statistical data for the market and provides profiles of 60 major tissue engineering market players. Future forecasts are also reviewed in detail.

Report Contents:

1. Introduction

2. Product Outline

2.1 Biomaterials

2.2 Cells

2.3 Biomolecules

2.4 Aspects of Engineering Design

2.5 Biomechanical Design Aspects

2.6 Informatics to Support Tissue Engineering

2.7 Stem Cell Research

2.8 Therapeutic Applications of Tissue Engineering and Regenerative Medicine

2.8.1 Orthopedic Applications

    2.8.1.1 Bone Regeneration Using Orthopedic Tissue Engineering

    2.8.1.2 Articular Cartilage Degeneration and Osteoarthritis, Repair, Regeneration and Transplantation

     2.8.1.2.1 Cartilage Repair

     2.8.1.2.2 Osteochondral Allograft Transplantation

2.8.2 Skin/Integumentary Applications

    2.8.2.1 Burns

    2.8.2.2 Diabetic Ulcers

    2.8.2.3 Venous Ulcers

    2.8.2.4 Plastic and Reconstructive Surgery

2.8.3 Oncology Applications

    2.8.3.1 Cancer

    2.8.3.2 Cancer Biology from Tissue Engineering’s Perspective

    2.8.3.3 Tissue Engineering Technology Platforms’ Translation into Cancer Research

2.8.4 Cardiovascular Applications

    2.8.4.1 Cardiac Tissue Engineering: An Overview

    2.8.4.2 Identification of Basic Cell Responses

     2.8.4.2.1 Materials and Degradation

     2.8.4.2.2 Attachment

     2.8.4.2.3 Stiffness

     2.8.4.2.4 Diffusion and Porosity

     2.8.4.2.5 Forces

    2.8.4.3 3-Dimensional Tissue Engineering

    2.8.4.4 Further 3-D Approaches and Considerations

    2.8.4.5 Cardiovascular Tissue Engineering and Bioreactor Technology

    2.8.4.6 Limiting Cells or Materials

2.8.5 Dental

    2.8.5.1 Dental Tissue Regeneration through Tissue Engineering Strategy

    2.8.5.2 Harvesting Teeth Created by Tissue Engineering

    2.8.5.3 Research Goals Currently Targeted

    2.8.5.4 Process of Tissue Engineering for Tooth Replacement: What Future Trends Indicate

2.8.6 Neurology Applications

    2.8.6.1 Neural Tissue Engineering or Neuroregeneration

    2.8.6.2 Biomaterial Scaffold Development for Nerve Tissue Engineering: Biomaterial Mediated Neural Regeneration

     2.8.6.2.1 Response to Injury and Repair

     2.8.6.2.2 Neural Cells’ Regeneration Potential

     2.8.6.2.3 Regeneration Promoted through Growth Factor Delivery

     2.8.6.2.4 Biomaterials in Nerve Regeneration

     2.8.6.2.5 Polymeric Scaffolds as Extracellular Matrix Analogues

     2.8.6.2.6 Geometric Indicators: Structure of Scaffolds

     2.8.6.2.7 Nanofiber Properties and Electrospinning Technology

     2.8.6.2.8 Alternate Approaches

     2.8.6.2.9 Electrical Cues

...

More new market research reports by the publisher can be found at Industry Experts page.

###

Tanya Rezler
The Market Publishers, Ltd
+44 208 144 6009
Email Information

Read the original post:
Global Tissue Engineering Market Review Recently Published at MarketPublishers.com

Read More...

GeneCell International’s Director of Research and Laboratory Operations is Invited to Speak at a Local Middle School …

February 23rd, 2012 6:46 pm

Dr. Todd Flower, Director of Research and Laboratory Operations at GeneCell International, has been invited to speak at the Jorge Mas Canosa Middle School on career day to a group of students about the science behind adult stem cells.

Miami, FL. (PRWEB) February 22, 2012

Dr. Todd Flower, Director of Research and Laboratory Operations at GeneCell International, has been invited to speak at the Jorge Mas Canosa Middle School on career day to a group of students about the science behind adult stem cells.

Dr. Todd R. Flower will be set to speak on Friday, March 9, 2012, from 9:40am to 1:30pm, to 4 different groups of 6th, 7th, and 8th grade students. The talk will be centered on the science of adult stem cells, its potential medical uses, as well as the use of liquid nitrogen and cryogenic procedures. “As a scientific institution, we need to educate the public and give back to our community, therefore, I look forward to meeting with this group of young bright individuals who we can hopefully inspire to become scientists”, said Dr. Todd R. Flower.    

Adult stem cells can be found and isolated from several different adult tissue types including but not limited to: bone marrow, umbilical cord blood, dental pulp tissue, adipose (fat) tissue, menstrual blood, synovial fluid etc. The stem cells isolated from these adult tissues have the ability to differentiate (mature into) numerous other cell types giving them the potential to treat a variety of different disease states.

GeneCell International is the only cutting-edge laboratory in Miami that specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including; umbilical cord blood, dental pulp and adipose (fat) tissue that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues.

“This opportunity allows us to further educate our community to ensure that everyone is given the best and most current information on preserving stem cells that can potentially save a life of a family member,” added GeneCell’s Operation’s Director, Jose Cirino.

Alongside its commitment to educating the public on the benefits of cord blood, dental pulp and adipose tissue preservation, GeneCell is committed to being on the forefront of stem cell research.

About GeneCell International

GeneCell International, LLC is a trusted provider in the collection, processing and storage of adult stem cells from various sources which have the potential to treat a variety of diseases and disorders. Headquartered in Miami, Florida and with local offices in Central Florida, Colombia, Rhode Island, the Dominican Republic, Panama and Venezuela, GeneCell operates state of the art laboratories and storage facilities for the cord blood of thousands of clients. For more information and to learn more about cord blood banking visit http://www.GeneCell.com

###

Lourdes Balestena, Public Relations
GeneCell International, LLC
305-300-0845
Email Information

Originally posted here:
GeneCell International’s Director of Research and Laboratory Operations is Invited to Speak at a Local Middle School ...

Read More...

MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to …

February 23rd, 2012 6:45 pm

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

More here:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

Read More...

MediVet-America Partners With Butler Schein Animal Health to Distribute World’s Leading Animal Stem Cell Technology to …

February 23rd, 2012 2:24 am

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

Read more:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

Read More...

VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

February 23rd, 2012 2:24 am

ATLANTA, GA--(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.

"VistaGen's work with human stem cell technology is groundbreaking," said Sherri Snyder, Director of Marketing at MissionIR. "The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates."

"We are pleased to bring MissionIR on board as our external investor relations partner," said Shawn Singh, VistaGen's Chief Executive Officer. "The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development."

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit http://www.MissionIR.com

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Read this article:
VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

Read More...

Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

February 23rd, 2012 2:24 am

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

"We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant," stated Dr. Franklin. "We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes."

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, "If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development."

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at http://www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. For more information please visit: http://www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

Read more:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

Read More...

Study: Stem Cells Reverse Heart Damage – Video

February 22nd, 2012 2:25 pm

15-02-2012 13:09 BY ALYSSA CARTEE ANCHOR MEGAN MURPHY A breakthrough discovery in stem cell treatments. A patient's own stem cells could actually regenerate the heart after a heart attack. WFLD explains the findings. "The studies found that recent heart attack victims who receive stem cell infusions had a drop in unhealthy heart scar tissue from 24 to 12 percent." The procedure is minimally invasive. A catheter is inserted through the patient's vein and a piece of heart muscle about the size of a peppercorn is removed. That biopsied tissue is then grown in a petri dish and reintroduced to the damaged portion of the heart. This new procedure could change the way heart attacks are treated. ABC reports the typical damage a heart attack leaves and the limited options for treatment. "The damaged scar tissue that results from a heart attack diminishes heart function, which can ultimately lead to enlargement of the heart. At best ... there are measures doctors can try to reduce or compensate for the damage, but in many cases, heart failure ultimately sets in, often requiring mechanical support or a transplant." But the new treatment challenges the conventional wisdom that once the heart is damaged, it can't be repaired. Doctor Sanjay Gupta told CNN this breakthrough in the use of stem cells means a few different things for the medical community. "We've been talking about the promise of stem cells for so long but people have really yet to see it in action. ... It really proved two things. First ...

View original post here:
Study: Stem Cells Reverse Heart Damage - Video

Read More...

UM human embryonic stem cell line placed on national registry – Video

February 22nd, 2012 2:25 pm

17-02-2012 08:27 The University of Michigan's first human embryonic stem cell line will be placed on the US National Institutes of Health's registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry. The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproduction but was no longer needed for that purpose and was therefore about to be discarded.

Read more from the original source:
UM human embryonic stem cell line placed on national registry - Video

Read More...

Scientists using stem cells to grow hamburger in a lab

February 22nd, 2012 2:25 pm

Test-tube burgers - coming soon to a restaurant near you?

A researcher from the Netherlands says he expects to grow the first-ever hamburger in a lab by this fall.  The beef will made from bovine stem cells grown in a petri dish.

Dr. Mark Post, the study leader, said the ultimate goal is the mass produce the lab meat in order to cut back on cattle farming.

Personally, I have a few problems with this study.  Yes, the beef will be made from stem cells, but don’t be confused: There is nothing natural about growing meat in the laboratory for human consumption.

With all the controversy on genetically altered food why in the world would we want to get into the business of creating hamburgers in a lab?

To me the whole concept of farming animals and crops is that the practice contributes to the natural process of life.  The more natural the process, the healthier it is, in my opinion.

Many of the medical crises we’re seeing in the world today are partly due to some of the unnatural ways we’re manufacturing food – from the chemicals to preserve the taste, to the hormones to increase the size of produce, to the pesticides to control production.  At the end of the day, all of these factors are taking a toll on our society.

Now, I’m familiar with stem cell research, and I’m sure that Dr. Holt is creating very pure forms of muscle cells, but I believe the focus of stem cell regeneration should continue to be for the quest to eradicate human diseases.

To take this promising medical technology and commercialize it in such a way to create a for-profit industry like making hamburger patties to stock your local grocery store is disrespectful to the thousands of scientists who have studied – and continue to study – the life-saving potential of stem cells.

But maybe I’m wrong – tell me what you think.  Would you eat this burger?

Go here to see the original:
Scientists using stem cells to grow hamburger in a lab

Read More...

New microfluidic device could be used to diagnose and monitor cancer and other diseases

February 22nd, 2012 2:25 pm

Mittal and his colleagues at MIT and Massachusetts General Hospital (MGH) have now demonstrated a new microfluidic device that can isolate target cells much faster than existing devices. Such technology could be used in applications such as point-of-care diagnostics and personalized medicine.

The researchers describe their results in the Feb. 21 issue of Biophysical Journal. Other authors of the paper are Ian Wong, a postdoc at MGH and Harvard Medical School (HMS), MIT chemical engineering professor William Deen, and Mehmet Toner, a professor of biomedical engineering at MGH, HMS and HST.

Researchers have used a number of techniques to sort cells based on differences in size, density or electrical properties. However, since the physical characteristics of cells can vary significantly, these techniques risk separating cells incorrectly, leading to an erroneous diagnosis. A more specific way to isolate cells is to use antibodies that latch on to distinctive molecules displayed on the surfaces of the target cells.

However, this selective approach only works if the target cells come into contact with the antibodies designed to capture them. This is unlikely to happen when the cells are moving at relatively high speeds.

“Imagine you’re standing on a bridge over a river, and you throw a message in a bottle out in the middle,” Wong says. “If the river is moving really slowly, you could imagine that eventually the bottle will drift over to the riverbank and somebody can grab it. But if the river is flowing too quickly, then the bottle is swept downstream without ever approaching the sides.”

That’s the problem the team needed to solve, Wong says: “Can we steer the bottle toward the riverbank so that it can get caught?” To achieve that, the MIT and MGH researchers designed their device to guide the fluid toward the bottom of the channel as it flows, bringing more of the cells in contact with the antibodies. Key to their new design is the use of a soft membrane with nanoscale pores, which separates two adjacent microchannels. 

Cells enter one channel only, and as they flow through the channel, the fluid is rapidly drawn to the porous divider, bringing the cells with it. Fluid can pass into the other channel, but the cells cannot. Once they reach the surface, they start rolling — slowly enough that target cells have time to attach to the antibodies and get captured, but fast enough to keep the other cells moving. Such rolling behavior is similar to how white blood cells or stem cells selectively “home in” to sites of infection and injury in the body. 

Shashi Murthy, an associate professor of chemical engineering at Northeastern University, says the device is simple but very well-designed. “The field of microfluidics is very largely done by experimental trial and error,” says Murthy, who was not involved in this research. “One seldom sees as in-depth an analysis, and one so well-grounded in theory.”

One potential application for these devices is to isolate cancer cells from patient blood samples. Toner’s group has previously shown that the number of circulating tumor cells in the bloodstream correlates with the clinical response to treatment in a given patient, suggesting the potential for personalized medicine for cancer patients. 

“Considerable validation and testing will be necessary before this early-stage device can be deployed in the clinic,” Toner says. “Nevertheless, this novel approach may enable exciting diagnostic and therapeutic opportunities that are not feasible using existing technologies.”

Provided by Massachusetts Institute of Technology (news : web)

This story is republished courtesy of MIT News (http://web.mit.edu/newsoffice/), a popular site that covers news about MIT research, innovation and teaching.

Original post:
New microfluidic device could be used to diagnose and monitor cancer and other diseases

Read More...

Qatari students to present research on stem cells

February 22nd, 2012 2:25 pm

Research on the potential of stem cells in preventing ovarian cancer, obesity-related diseases and other serious illnesses affecting people in Qatar and the region is to be presented by three Qatari graduate students at the Qatar International Conference on Stem Cell Science and Policy next week.
The conference is organised by Qatar Foundation for Education, Science and Community Development (QF) and James A Baker III Institute for Public Policy.
It will provide an international platform to discuss the latest discoveries in stem cell research and collaborate on new therapeutic approaches for the use of stem cells, within an acceptable ethics, cultural and religious framework.
The students are part of QF’s Qatar Science Leadership Programme (QSLP), and their participation in the conference is considered an important part of their training. 
With more than 400 registered participants, including key ethicists and scientists in stem cell research, the conference provides students invaluable opportunities for exchanging knowledge and building relationships with top figures and leading regional and international institutions in the field.
QSLP, aims to equip rising Qatari generations for leading roles in the country’s scientific and research endeavours, with stem cell research as a national priority.
Qatari QSLP trainee and PhD student from Paris XI University, Dr Hamda al-Thawadi, will present at the conference a poster about her research on ovarian cancer.
She explained that this is an important area specifically for Qatar, as there is a high prevalence of thrombotic diseases which affect patients with cancer.
“My project will help in detecting a powerful tool for the assessment of thrombosis risk factors in patients with cancer as well as healthy individuals, which should help develop preventative measures,” she said.
Dr Halema Alfarsi, another student on QSLP’s scientific track, is also presenting her research on ovarian cancer at the conference. Her work explores the potential application of stem cells in making cells and tissues for medical therapies.
She pointed out that currently, donated tissues and organs are often used to replace those that are diseased or destroyed. Stem cells offer a viable source of replacement cells to treat diseases and can potentially reduce the morbidity and mortality for those awaiting transplants for Parkinson’s disease, spinal cord injury, severe burns, diabetes and arthritis.
“In Qatar we have many cases of cancer, diabetes, heart disease and arthritis. Stem cells offer hope for effective treatment or perhaps even reversal of the disease,” added Dr Alfarsi.
The recently published Heba al-Siddiqi, another QSLP student, will present her research on preventing chronic obesity-related diseases through tissue engineering and organ regeneration. This research was recently featured in the leading international scientific journal Nature.
“Tackling obesity-related diseases such as coronary heart disease and type 2 diabetes through developing stem cell technology is very important as these diseases are increasingly common in Qatar,” observed al-Siddiqi.
“I am excited about the potential of creating cell-based therapies to treat and prevent chronic diseases in Qatar for future generations,” she added.
The three student presenters will be joined at the conference by their fellow QSLP members, Sarah Ali Abdulla and Abeer al-Shammari. 
Abdulla, who is pursuing her PhD in stem cell science and neuroscience at the University of Cambridge, will serve as master of ceremonies over the conference’s four days.
“The Qatar conference on stem cells supports our students’ scientific development by including them in the country’s stem cell research community and connecting them with leading figures in the field. We hope it will inspire young people in Qatar and the region to pursue studies in stem cell science,” said QF’s head of Research Training and Development, Dr Ayman Bassil.
The Qatar International Conference on Stem Cell Science and Policy opens on February 27, 2012 at the Qatar National Convention Centre. 
More information about the conference can be found at http://www.qf-research-division.org/stemcell2012

See the original post here:
Qatari students to present research on stem cells

Read More...

Carrboro man to get stem cell transplant

February 22nd, 2012 2:25 pm

Published: Feb 22, 2012 02:00 AM
Modified: Feb 20, 2012 10:41 PM


Carrboro man to get stem cell transplant
Treatment a first at UNC

BY ELIZABETH SWARINGEN, Special to The Chapel Hill News

CHAPEL HILL - Three infusions of your own stem cells - each infusion over a 21-day hospitalization - can seem daunting. But, when it's your best chance for beating a recurrence of testicular cancer, you look forward to it."It doesn't seem intimidating to me at all," said David Alston, 42, of Carrboro. "You don't normally think of stem cell bone marrow transplants as treatment for testicular cancer, but it has been done in New York with success. I'm pleased it's available to me here at UNC Hospitals."This month Alston is having the first triple-tandem transplant done in an adult at UNC Hospitals.The process involves harvesting and freezing his own stem cells, receiving high-dose chemotherapy to attack the cancer, then having the stem cells infused over three back-to-back hospitalizations."He's young and otherwise healthy, and we think this is the right thing for him," said Dr. Paul M. Armistead, assistant professor of medicine in the Division of Hematology/Oncology, a member of the UNC Lineberger Comprehensive Cancer Center and leader of Alston's transplant team. "This is his best chance for being cured."Alston, a Charlotte native, was diagnosed with aggressive testicular cancer in March 2011 after experiencing an "avalanche of symptoms.""I didn't have a lump, but I had some weird back pain and loss of feeling in one leg," David said. "By the time I had some scans, we found lymph node involvement in a lot of places. Essentially, the cancer had gone on vacation all over my body."Testicular cancer is one of the more curable cancers, often cured in the first round of chemotherapy, said Dr. Kim Rathmell, associate professor of medicine, a member of UNC Lineberger Comprehensive Cancer Center and Alston's medical oncologist.Aggressive chemotherapy sent the cancer into remission, and by August Alston returned to his long-time job at Weaver Street Market in Chapel Hill's Southern Village.Routine blood test results in December surprised everyone: the cancer was back."Because of the way David's cancer came back, a more aggressive approach than chemotherapy alone was needed," said Rathmell, adding how hard it was knowing Alston faced treatment again. "I shop that store, and I had seen him back at work."Dr. Matthew Milowsky, who participated in the development of the triple-tandem transplant for testicular cancer at Memorial Sloan Kettering in New York City, joined UNC Lineberger Comprehensive Cancer Center last fall as co-director of UNC's urologic oncology program. Rathmell quickly recruited him to Alston's team."We have everything we need here at UNC to treat David," Rathmell said. "Had David come to us five years ago, when this recommended treatment was newer and we didn't have local expertise, I would likely have referred him elsewhere. Today, we are very comfortable doing this transplant here. And it's a total team approach."In January, Alston began receiving two types of chemotherapy to mobilize his stem cells in preparation for collection.This chemotherapy featured one less drug than what he endured after initial diagnosis and yielded fewer side effects."It was night and day difference," he said, remembering the physical and mental side effects that sent him into the ICU last spring. "By comparison, what I'm doing in preparation for the transplant has been rather effortless."But the process is complicated and has many moving parts."David will have five chemotherapy infusions administered by two separate medical teams that have to work together through a lot of logistics about what happens when," said Armistead. "That David is organized and intelligent and sends a lot of questions to Dr. Rathmell and me via email, he's helping himself stay on top of things. Having a patient who is fully aware of what's going on has kept us on our toes and helped us develop and coordinate a more fool-proof system."Still, as a single, stubbornly independent man, Alston needed help and support. Luckily, his mother, Barbara Alston, a retired medical professional from Concord, is by his side.Both are staying at SECU Family House, the 40-bedroom hospital hospitality house minutes from UNC Hospitals for seriously ill adult patients and their family member caregivers.The Alstons will stay at Family House during the nine weeks total that David is expected to be hospitalized. He will join her between transplants and for post-transplant monitoring."It's a comfort being here at Family House," Barbara Alston said. "If we need something, it's taken care of, both here and at the hospital. I'm assured David's getting the care he needs. I'm helping him whenever and wherever I can."SECU Family House will play an even larger role in Alston's recovery post-transplant, both Rathmell and Armistead agreed."This treatment is intense, and David will be more in the hospital than out," Rathmell said. "He will need a solid support system, and he has that with his mother. It's a fragile time, and she has his best interest at heart.""Post-transplant David will need to be monitored closely because his immune system will be very weak," Armistead said. "His mother's medical background is a bonus. The Family House folks are used to immune-suppressed patients and can get them to the hospital quickly if needed."Alston has kept himself swimming in information to minimize the fear and mystery. Barbara has been the great translator when his own efforts didn't yield the level of detail he needed."The constant learning gives it all a degree of routine that took some of the scariness away," Alston said. "But you can't be too independent or too brainy when you have cancer."Cancer blows you out of the water, but it leaves you with valuable insight," he said. "How you deal with cancer is self-guided and you learn things about yourself and your personality that you never knew. It's the ultimate in snatching the silver lining from a cloud."

Elizabeth Swaringen wrote this article for UNC Health Care.

Read more:
Carrboro man to get stem cell transplant

Read More...

Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

February 22nd, 2012 2:25 pm

NOKOMIS, Fla.--(BUSINESS WIRE)--

Research into Cancer Stem Cells (CSC) is on the rise, fueling industry growth that Rainbow Coral Corp. (OTCBB: RBCC.OB - News) expects to translate into demand for n3D cell growth technologies.

RBCC is finalizing an equity funding agreement with n3D Biosciences, the maker of a revolutionary new system that allows scientists to grow three-dimensional cell cultures more easily than ever before. The device, called the Bio-Assembler, could have an extraordinary impact on cell research worldwide, and RBCC expects to find a strong market for the device once its funding agreement with n3D is finalized.

Many cancers, including breast, prostate, pancreatic, colon, brain, and lung cancers, contain a subset of stem-like cells understood to play a critical role in the development and progression of the disease. Research suggests that these cells, called Cancer Stem Cells, are able to “seed” new tumor formation and drive metastasis.

Because these cells are believed to be at the root of the development and spread of cancer, they’re quickly becoming the center of cancer diagnostics and biomarkers. CSCs are resistant to a number of chemotherapy drugs and radiotherapy, and approximately 20 different strategies are currently being pursued in the hope of selectively targeting CSCs. This creates a huge opening for new companies and technologies dedicated to streamlining cellular research.

RBCC believes that the Bio-Assembler could allow researchers to dramatically shorten the development timeline for new CSC drugs and treatments, potentially proving very lucrative to the company.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Read the rest here:
Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Read More...

Stem cell implants boost monkeys with Parkinson's

February 22nd, 2012 2:25 pm

Monkeys suffering from Parkinson's disease show a marked improvement when human embryonic stem cells are implanted in their brains, in what a Japanese researcher said Wednesday was a world first.

A team of scientists transplanted the stem cells into four primates that were suffering from the debilitating disease.

The monkeys all had violent shaking in their limbs -- a classic symptom of Parkinson's disease -- and were unable to control their bodies, but began to show improvements in their motor control after about three months, Kyoto University associate professor Jun Takahashi told AFP.

About six months after the transplant, the creatures were able to walk around their cages, he said.

"Clear improvements were confirmed in their movement," he said.

Parkinson's disease is a progressive neurological illness linked to a decrease in dopamine production in the brain. There is currently no medical solution to this drop off in a key neurotransmitter.

The condition, which generally affects older people, gained wider public recognition when Hollywood actor Michael J. Fox revealed he was a sufferer.

Takahashi said at the time of the implant about 35 percent of the stem cells had already grown into dopamine neuron cells, with around 10 percent still alive after a year.

He said he wants to improve the effectiveness of the treatment by increasing the survival rate of dopamine neuron cells to 70 percent.

"The challenge before applying it to a clinical study is to raise the number of dopamine neuron cells and to prevent the development of tumours," he said.

"I would like to make this operation more effective and safe" before clinical trials, Takahashi said.

Takahashi said so far he had used embryonic stem cells, which are harvested from foetuses, but would likely switch to so-called Induced Pluripotent Stem (iPS) cells, which are created from human skin, for the clinical trial.

His team, which has also transplanted iPS cells into monkeys, are now looking to see if the primates with Parkinson's disease show similar improvements in their motor control.

Scientists say the use of human embryonic stem cells as a treatment for cancer and other diseases holds great promise, but the process has drawn fire from religious conservatives, among others.

Opponents say harvesting the cells, which have the potential to become any cell in the human body, is unethical because it involves the destruction of an embryo.

The Japanese government currently has no guidelines on the use of human stem cells in clinical research.

In October last year, the Court of Justice of the European Union banned the patenting of stem cells when their extraction causes the destruction of a human embryo, a ruling that could have repercussions on medical research.

Scientists warned that the ruling would damage stem cell research in Europe, while the Catholic church hailed it as a victory for the protection of human life.

See original here:
Stem cell implants boost monkeys with Parkinson's

Read More...

China medicdal tourism– Cirrhosis–Stem cells therapy 1.mp4 – Video

February 22nd, 2012 2:24 pm

16-02-2012 20:19 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Adult stem cells provide real improvement for cirrhosis patients Breakthrough adult stem cell research has shown that stem cells are able to regenerate and repair damaged or destroyed liver cells. For patients with cirrhosis, this means improved liver function, decreased pain and a significantly improved quality of life. Stem cell therapy offers the safest and most effective treatment alternative for liver cirrhosis and it is quickly becoming a preferred treatment in Asia. China medical tourism offers unique access to the best stem cell therapies available at leading medical facilities. Supporting data and statistics Three out of every four patients treated experienced a significant improvement in their condition following stem cell treatment. The following clinical results were observed: •Improved liver function •Decreased pain •Improved values for liver function, PLT (blood platelet) and blood ammonia You may see improvements during your hospitalization due to neurotrophic factors released during the stem cell transplantation, which stimulate nerve activity; new cells will grow for up to six months after you ...

Original post:
China medicdal tourism-- Cirrhosis--Stem cells therapy 1.mp4 - Video

Read More...

China medicdal tourism– Cirrhosis–Stem cells therapy 2.mp4 – Video

February 22nd, 2012 2:24 pm

19-02-2012 22:06 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Adult stem cells provide real improvement for cirrhosis patients Breakthrough adult stem cell research has shown that stem cells are able to regenerate and repair damaged or destroyed liver cells. For patients with cirrhosis, this means improved liver function, decreased pain and a significantly improved quality of life. Stem cell therapy offers the safest and most effective treatment alternative for liver cirrhosis and it is quickly becoming a preferred treatment in Asia. China medical tourism offers unique access to the best stem cell therapies available at leading medical facilities. Supporting data and statistics Three out of every four patients treated experienced a significant improvement in their condition following stem cell treatment. The following clinical results were observed: •Improved liver function •Decreased pain •Improved values for liver function, PLT (blood platelet) and blood ammonia You may see improvements during your hospitalization due to neurotrophic factors released during the stem cell transplantation, which stimulate nerve activity; new cells will grow for up to six months after you ...

See the article here:
China medicdal tourism-- Cirrhosis--Stem cells therapy 2.mp4 - Video

Read More...

Renato Dulbecco dies at 97; 1975 Nobel Prize winner in medicine

February 22nd, 2012 2:24 pm

Dr. Renato Dulbecco, an Italian American virologist who shared the 1975 Nobel Prize in physiology or medicine for demonstrating how certain types of viruses invade mammalian cells to cause cancer, died of natural causes Sunday at his home in La Jolla. He was 97.

Dulbecco developed a method for measuring the quantity of virus in animal cells in tissue culture, a finding that greatly facilitated the study of such viruses and paved the way for the development of the Sabin polio vaccine. He was a faculty member at Caltech from 1949 to 1963 before moving to the Salk Institute for Biological Studies in La Jolla. He later served as president of the institute.

FOR THE RECORD:
Renato Dulbecco: A news obituary in the Feb. 21 LATExtra section of Nobel Prize-winning virologist Renato Dulbecco misspelled the first name of Italian anatomist Giuseppe Levi as Giuseppi. —

Dulbecco was also one of the first proponents of the human genome project, which many researchers initially thought would be both excessively expensive and relatively useless but which has since proved invaluable in biological research.

"Renato was one of the most brilliant scientific minds of our generation," current Salk Institute President William R. Brody said in a statement. "His contributions have truly made this a better world for all of us."

It has been known since the early 1900s that certain viruses can cause tumors in animals. The best-known example was the Rous sarcoma virus, which causes cancer in chickens. But it was not clear how the viruses produced this effect and what proportion of human cancers might be attributed to them.

In experiments carried out at Caltech in the 1950s, Dulbecco showed that a viral infection can have two outcomes: the virus can multiply inside the cell, killing the cell and releasing thousands of new viruses into the host animal; or it could alter the cell so that the cell would continue to divide and grow indefinitely, a process called transformation.

In the latter case, no new virus particles appear and the infecting virus seemingly disappears.

Through an elegant series of experiments, Dulbecco showed that the DNA from the polyoma virus became integrated into the DNA of the host cell, where it was replicated intact every time the cell replicated. Moreover, the viral DNA served as the blueprint for a small number of proteins that subverted cellular machinery, causing the cells to reproduce repeatedly — the hallmark of tumor formation.

Additionally, this feat was achieved before it was possible to sequence the DNA of either viruses or animal cells.

For his achievement, Dulbecco shared the 1975 Nobel Prize with Howard Temin and David Baltimore, who demonstrated the existence of an enzyme — reverse transcriptase — that allowed RNA viruses to integrate their genes into a host cell in the same fashion as the DNA viruses studied by Dulbecco. Both were former students of his.

In his Nobel address, Dulbecco called for increased restrictions on tobacco use because of its carcinogenic potential and urged governments to make greater efforts to limit the introduction of dangerous chemicals.

"While we spend our life asking questions about the nature of cancer and ways to prevent or cure it," he said, "society merrily produces oncogenic substances and permeates the environment with them."

Renato Dulbecco was born Feb. 22, 1914, in Catanzaro, Italy, the son of a civil engineer. He enrolled at the University of Turin, where he had meant to study physics and chemistry but soon became interested in biology instead.

He received his medical degree in 1936 and during World War II served in France and Russia, where he was injured in 1942 during a major Russian offensive along the Don River.

After several months of hospitalization, he returned home, hiding out in a small village near Turin when German forces occupied Italy after Mussolini's fall. He served as a medical officer for partisan forces resisting the occupation.

In medical school, Dulbecco had worked in the laboratory of noted anatomist Giuseppi Levi, along with fellow students Salvador Luria and Rita Levi-Montalcini, both of whom also became Nobel laureates. In 1946, Luria invited Dulbecco to join his small laboratory at the Indiana University and Dulbecco immigrated the following year, becoming a U.S. citizen in 1953. At IU, he shared bench space with James Watson, another eventual Nobel laureate.

Dulbecco was working with bacteriophage, small viruses that invade only bacteria cells. He showed that bacteriophage that had been disabled by exposure to ultraviolet light could be reactivated by exposing them to bursts of white light.

That work attracted the attention of microbiologist Max Delbruck, who invited Dulbecco to join him at Caltech. In the summer of 1949, Dulbecco and his then-wife, the former Giuseppina Salvo, drove an old car cross-country. He wrote in his Nobel autobiography that he was struck by "the beauty and immensity of the U.S.A. and the kindness of its people" and vowed to continue to live here forever.

While at Caltech, Dulbecco adapted a technique he had used with bacteriophage to count the number of virus particles that are present in a tissue sample. Dubbed the plaque assay technique, the assay relies on the fact that viruses added to a culture of cells kill small areas of cells, producing clear circles that can be counted.

This technique enabled researchers for the first time to measure the concentrations of virus in a sample and was crucial to Albert Sabin's work in inventing an attenuated virus polio vaccine. Dulbecco, in fact, originally isolated the mutant polio virus used by Sabin in his vaccine.

In 1962, Dulbecco became a founding member of the Salk Institute, where he remained for the rest of his career. He also spent time at the Imperial Cancer Fund Research Laboratories in London, where he worked on human cancer viruses, although he remained on the staff at Salk. In his later years, he researched breast cancer and concluded that breast cancer stem cells gone awry might be responsible for certain types of breast tumors.

In 1988, he became interim president at Salk, a position that soon became permanent. He held the post until he returned to his laboratory research in 1992.

During the 1980s, Dulbecco had argued passionately in favor of a human genome project. After his retirement as Salk president he was asked by the Italian National Research Council to develop an Italian human genome project, and he spent about half his time each year in that country. The project was abandoned after five years, however, because of lack of funding and facilities.

Dulbecco was a classically trained pianist who was passionate about music and performed opera. He was also a dedicated do-it-yourself handyman and once told The Times, "If I can get a week off to work on the house, that's the best vacation I can get." He remodeled his kitchen and added about 1,000 square feet of space to his home in La Jolla, performing all the work — including plumbing and electrical — himself.

Dulbecco is survived by his second wife, Maureen, whom he married in 1962; a brother, two daughters and four grandchildren. A son predeceased him.

Maugh is a former Los Angeles Times staff writer.

news.obits@latimes.com

See original here:
Renato Dulbecco dies at 97; 1975 Nobel Prize winner in medicine

Read More...

Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA

February 22nd, 2012 2:24 pm

VILLA GUARDIA, Italy, Feb. 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT - News) (the "Company") announced today that it has submitted its response to the Day 120 List of Questions (the "LoQs") issued by the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") with respect to the Company's Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy.

"We are pleased to announce that we have finalized and submitted written responses to the LoQs," said Dr. Khalid Islam, Chairman & Chief Executive Officer of the Company. "We plan to continue working closely with the EMA towards the approval of Defibrotide."

Following the submission of the Day 120 LoQs responses, the CHMP will continue its review of the MAA and will either issue an opinion on the MAA or submit a List of Outstanding Issues (LoOIs) requiring further clarification, the latter of which will stop the review clock to permit the Company time to respond. The CHMP is expected to reach its final opinion no later than day 210 calculated based on the EMA review process timeline.

The Company submitted its MAA for Defibrotide to the EMA in May 2011 and the CHMP issued the LoQs at the end of September 2011.

About the EMA Review Process:

Following the submission of its response to the Day 120 LoQs, the Company may meet with the Rapporteur and Co-Rapporteur to clarify the intent behind the questions presented and obtain further information regarding the CHMP's concerns. The EMA's review will resume on day 121 with any further communication from the EMA anticipated by day 150 under the accelerated review timeline (or day 180 under the standard review timeline if accelerated review is not permitted). At that point, the EMA is expected to either submit an LoOI or issue an opinion on the MAA. EMA guidelines permit companies in receipt of an LoOI to respond within one month. More information can be obtained from the EMA website http://www.ema.europa.eu.

About VOD

Veno-occlusive disease is a potentially life-threatening condition, which typically occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplantation can damage the lining cells of hepatic blood vessels and result in VOD, a blockage of the small veins in the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). Stem cell transplantation is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. At present there is no approved agent for the treatment or prevention of VOD in the United States or the European Union.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency, both to treat and to prevent VOD, as well as Fast Track Designation by the U.S. FDA to treat VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."

Read more:
Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA

Read More...

Page 1,508«..1020..1,5071,5081,5091,510..1,5201,530..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick